We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
Read MoreHide Full Article
Canopy Growth Corporation (CGC - Free Report) closed the most recent trading day at $42.77, moving +1.59% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.76%. Elsewhere, the Dow gained 0.67%, while the tech-heavy Nasdaq added 0.71%.
Prior to today's trading, shares of the company had gained 49.82% over the past month. This has outpaced the Medical sector's loss of 1.02% and the S&P 500's gain of 0.75% in that time.
Investors will be hoping for strength from CGC as it approaches its next earnings release, which is expected to be February 14, 2019. In that report, analysts expect CGC to post earnings of -$0.07 per share. This would mark year-over-year growth of 36.36%. Our most recent consensus estimate is calling for quarterly revenue of $78.97 million, up 362.08% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.87 per share and revenue of $221.12 million, which would represent changes of -171.88% and +262.77%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for CGC. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.52% higher within the past month. CGC is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CGC in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know
Canopy Growth Corporation (CGC - Free Report) closed the most recent trading day at $42.77, moving +1.59% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.76%. Elsewhere, the Dow gained 0.67%, while the tech-heavy Nasdaq added 0.71%.
Prior to today's trading, shares of the company had gained 49.82% over the past month. This has outpaced the Medical sector's loss of 1.02% and the S&P 500's gain of 0.75% in that time.
Investors will be hoping for strength from CGC as it approaches its next earnings release, which is expected to be February 14, 2019. In that report, analysts expect CGC to post earnings of -$0.07 per share. This would mark year-over-year growth of 36.36%. Our most recent consensus estimate is calling for quarterly revenue of $78.97 million, up 362.08% from the year-ago period.
For the full year, our Zacks Consensus Estimates are projecting earnings of -$0.87 per share and revenue of $221.12 million, which would represent changes of -171.88% and +262.77%, respectively, from the prior year.
Investors might also notice recent changes to analyst estimates for CGC. These revisions help to show the ever-changing nature of near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.52% higher within the past month. CGC is currently a Zacks Rank #3 (Hold).
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 90, which puts it in the top 36% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow CGC in the coming trading sessions, be sure to utilize Zacks.com.